{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:35:42Z","timestamp":1794335742105,"version":"4.9.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2020-02002"],"award-info":[{"award-number":["2020-02002"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Regional Agreement on Medical Training and Clinical Research"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["RS2021-0855"],"award-info":[{"award-number":["RS2021-0855"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cancer incidence data including absolute risk differences are needed for clinical risk communication to patients receiving modern-day treatments for ulcerative colitis (UC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We linked nationwide Swedish health registers and assessed incident cancers in patients with UC in 2007-2022. We computed age-stratified incidence rates (IRs), IR differences, and hazard ratios (HRs) in a na\u00efve cohort with no immunomodulatory treatment, and in cohorts treated with thiopurine or targeted therapies. General population comparator subjects were matched (by age, sex, calendar year, and area of residence) to each treatment cohort. We used a once-exposed\u2014always-exposed design.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 63\u00a0925 patients with UC in partly overlapping cohorts and 593\u00a0072 comparators with a total follow-up time of 5\u00a0800\u00a0089 years (median 8.1 years). The IRs were elevated compared to the general population in na\u00efve patients: 2.7 extra cancer cases per 1000 person-years (HR: 1.12, 95% CI, 1.09-1.16), in thiopurine-treated patients: 3.4 extra cases (HR: 1.48;1.37-1.61), tumor necrosis factor inhibitor (TNFi)-treated: 2.7 extra cases (HR: 1.41;1.24-1.62), Thiopurine\u2005+\u2005TNFi-treated: 2.42 extra cases (HR: 1.44;1.19-1.75), vedolizumab-treated: 2.88 extra cases (HR: 1.27;0.90-1.79). The IR differences were not significantly increased in patients treated with ustekinumab 0.57 (HR: 0.87;0,39-1.93) and tofacitinib \u22120.69 (HR: 0.84;0.25-2.77). Across all treatment groups, the IR differences compared to the general population were highest in patients\u2005\u2265\u200560 years. The differences were driven by colorectal cancer, hepatobiliary cancer, lymphoma, and basal cell skin carcinoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Elevated cancer incidence was observed in patients with UC amounting to around 3 extra cases of cancer per 1000 years. Cancer risks varied more among groups defined by age than by treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf091","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T17:15:21Z","timestamp":1748884521000},"source":"Crossref","is-referenced-by-count":12,"title":["Cancer incidence in patients with ulcerative colitis na\u00efve to or treated with thiopurine and targeted therapies\u2014a cohort study 2007 to 2022 with comparison to the general population"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0311-8894","authenticated-orcid":false,"given":"\u00c5sa H","family":"Everhov","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"S\u00f6derling","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0122-7234","authenticated-orcid":false,"given":"Jonas","family":"Halfvarson","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E","family":"Smedby","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Hematology, Theme Cancer, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas F","family":"Ludvigsson","sequence":"additional","affiliation":[{"name":"Department Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Pediatrics, \u00d6rebro University Hospital, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Toft","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Ol\u00e9n","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Pediatric Gastroenterology and Nutrition, Sachs\u2019 Children and Youth Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"2025063009413790800_CIT0001","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2025063009413790800_CIT0002","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","article-title":"Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis","volume":"14","author":"Shah","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025063009413790800_CIT0003","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794","article-title":"Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment","volume":"22","author":"Axelrad","year":"2016","journal-title":"World J Gastroenterol."},{"key":"2025063009413790800_CIT0004","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-020-0747-9","article-title":"The complex interplay between inflammatory bowel disease and malignancy","volume":"22","author":"Kimmel","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"key":"2025063009413790800_CIT0005","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.21037\/jgo-21-624","article-title":"Correlation of ulcerative colitis and colorectal cancer: a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"2025063009413790800_CIT0006","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(19)32545-0","article-title":"Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study","volume":"395","author":"Olen","year":"2020","journal-title":"Lancet."},{"key":"2025063009413790800_CIT0007","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/apt.17175","article-title":"Colorectal cancer in elderly-onset inflammatory bowel disease: a 1969-2017 Scandinavian register-based cohort study","volume":"56","author":"Everhov","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"key":"2025063009413790800_CIT0008","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/MPG.0000000000003574","article-title":"Colorectal cancer in childhood-onset inflammatory bowel disease: a Scandinavian register-based cohort study, 1969-2017","volume":"75","author":"Everhov","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2025063009413790800_CIT0009","doi-asserted-by":"crossref","first-page":"13599","DOI":"10.1002\/cam4.6057","article-title":"Inflammatory bowel disease increases the risk of hepatobiliary pancreatic cancer: a two-sample Mendelian randomization analysis of European and East Asian populations","volume":"12","author":"Huang","year":"2023","journal-title":"Cancer Med"},{"key":"2025063009413790800_CIT0010","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1055-9965.EPI-20-1241","article-title":"Hepatobiliary cancer risk in patients with inflammatory bowel disease: a Scandinavian population-based cohort study","volume":"30","author":"Erichsen","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025063009413790800_CIT0011","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cgh.2020.08.015","article-title":"The risk of extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies","volume":"19","author":"Lo","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025063009413790800_CIT0012","first-page":"e220595","article-title":"Development of cancer among patients with pediatric-onset inflammatory bowel disease: a meta-analysis of population-based studies","author":"Elmahdi","year":"2022"},{"key":"2025063009413790800_CIT0013","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ecco-jcc\/jjy006","article-title":"Reduced risk of inflammatory bowel disease-associated colorectal neoplasia with use of thiopurines: a systematic review and meta-analysis","volume":"12","author":"Zhu","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2025063009413790800_CIT0014","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/apt.14436","article-title":"Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease","volume":"47","author":"Lu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025063009413790800_CIT0015","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.cgh.2014.05.019","article-title":"Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis","volume":"12","author":"Jess","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025063009413790800_CIT0016","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025063009413790800_CIT0017","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jgh.14533","article-title":"Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"34","author":"Huang","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"key":"2025063009413790800_CIT0018","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2025063009413790800_CIT0019","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1053\/j.gastro.2020.12.036","article-title":"Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis","volume":"160","author":"Wijnands","year":"2021","journal-title":"Gastroenterology."},{"key":"2025063009413790800_CIT0020","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","volume":"52","author":"Chupin","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025063009413790800_CIT0021","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/apt.15692","article-title":"Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease","volume":"51","author":"Piovani","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025063009413790800_CIT0022","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025063009413790800_CIT0023","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ecco-jcc\/jjy096","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with anti-tumour necrosis factor alpha agents: a systematic review and meta-analysis","volume":"12","author":"Yang","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2025063009413790800_CIT0024","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025063009413790800_CIT0025","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025063009413790800_CIT0026","doi-asserted-by":"crossref","first-page":"e00513","DOI":"10.14309\/ctg.0000000000000513","article-title":"Risk of cervical cancer in inflammatory bowel disease: a meta-analysis of population-based studies","volume":"13","author":"Mann","year":"2022","journal-title":"Clin Transl Gastroenterol."},{"key":"2025063009413790800_CIT0027","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.12624","article-title":"Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease","volume":"39","author":"Williams","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2025063009413790800_CIT0028","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.3390\/cancers15082197","article-title":"Cancer risk in patients treated with the JAK inhibitor tofacitinib: systematic review and meta-analysis","volume":"15","author":"Bezzio","year":"2023","journal-title":"Cancers (Basel)."},{"key":"2025063009413790800_CIT0029","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"2025063009413790800_CIT0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/CLEP.S314959","article-title":"Nordic health registry-based research: a review of health care systems and key registries","volume":"13","author":"Laugesen","year":"2021","journal-title":"Clin Epidemiol."},{"key":"2025063009413790800_CIT0031","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/00365521.2019.1660799","article-title":"Swedish inflammatory bowel disease register (SWIBREG) - a nationwide quality register","volume":"54","author":"Ludvigsson","year":"2019","journal-title":"Scand J Gastroenterol."},{"key":"2025063009413790800_CIT0032","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2025063009413790800_CIT0033","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bcpt.12613","article-title":"The First decade with the swedish prescribed drug register - a systematic review of the output in the scientific literature","volume":"119","author":"Wallerstedt","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025063009413790800_CIT0034","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/00365521.2021.1884894","article-title":"Capturing biologic treatment for IBD in the Swedish prescribed drug register and the swedish national patient register - a validation study","volume":"56","author":"Broms","year":"2021","journal-title":"Scand J Gastroenterol."},{"key":"2025063009413790800_CIT0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"key":"2025063009413790800_CIT0036","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","article-title":"Registers of the Swedish total population and their use in medical research","volume":"31","author":"Ludvigsson","year":"2016","journal-title":"Eur J Epidemiol."},{"key":"2025063009413790800_CIT0037","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/00365521.2018.1564361","article-title":"Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients","volume":"54","author":"Everhov","year":"2019","journal-title":"Scand J Gastroenterol."},{"key":"2025063009413790800_CIT0038","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/00365521.2016.1246605","article-title":"Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG)","volume":"52","author":"Jakobsson","year":"2017","journal-title":"Scand J Gastroenterol."},{"key":"2025063009413790800_CIT0039","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12911-019-0948-z","article-title":"Validating surgical procedure codes for inflammatory bowel disease in the Swedish National Patient Register","volume":"19","author":"Forss","year":"2019","journal-title":"BMC Med Inform Decis Mak."},{"key":"2025063009413790800_CIT0040","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.cgh.2024.08.006","article-title":"Thiopurines and the risk of cancer in patients with inflammatory bowel disease and reference individuals without inflammatory bowel disease - a Danish Nationwide Cohort Study (1996-2018)","volume":"23","author":"Wewer","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025063009413790800_CIT0041","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/apt.17123","article-title":"Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease","volume":"56","author":"Biron","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2025063009413790800_CIT0042","first-page":"297","article-title":"Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden","volume":"70","author":"Axelrad","year":"2021","journal-title":"Gut."},{"key":"2025063009413790800_CIT0043","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/apt.15785","article-title":"Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969-2017","volume":"52","author":"Everhov","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025063009413790800_CIT0044","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1016\/j.cgh.2023.04.001","article-title":"Increasing risk of lymphoma over time in Crohn\u2019s disease but not in ulcerative colitis: a Scandinavian Cohort Study","volume":"21","author":"Ol\u00e9n","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025063009413790800_CIT0045","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"2025063009413790800_CIT0046","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/ibd\/izac171","article-title":"Risks of melanoma and nonmelanoma skin cancers pre- and post-inflammatory bowel disease diagnosis","volume":"29","author":"Narous","year":"2023","journal-title":"Inflamm Bowel Dis."},{"key":"2025063009413790800_CIT0047","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European Evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf091\/63418941\/jjaf091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/6\/jjaf091\/63418941\/jjaf091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/6\/jjaf091\/63418941\/jjaf091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T13:41:51Z","timestamp":1751290911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf091\/8155306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf091","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"jjaf091"}}